Found this article while looking around late tonight.. Mentions the clinical trial comparing Orthocell’s tendon regeneration therapy to corticosteroids is on track for recruitment completion by the second quarter of CY2019 as well as OCC revenue having increased 80% in the last 9 months for the corresponding previous 9 months.
https://kalkinemedia.com/news/orthocells-shares-rose-on-asx-post-application-to-tga-for-approval-of-celgro/
- Forums
- ASX - By Stock
- OCC
- Ann: First Patients Complete Nerve Regeneration Trial
Ann: First Patients Complete Nerve Regeneration Trial, page-538
Featured News
Add OCC (ASX) to my watchlist
|
|||||
Last
36.5¢ |
Change
0.005(1.39%) |
Mkt cap ! $76.40M |
Open | High | Low | Value | Volume |
36.5¢ | 37.0¢ | 36.0¢ | $2.864K | 7.871K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 136618 | 36.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 4400 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 86618 | 0.360 |
6 | 27365 | 0.355 |
7 | 149716 | 0.350 |
4 | 108988 | 0.345 |
1 | 25000 | 0.340 |
Price($) | Vol. | No. |
---|---|---|
0.365 | 4400 | 1 |
0.370 | 11312 | 2 |
0.375 | 32756 | 2 |
0.380 | 6345 | 2 |
0.385 | 72893 | 2 |
Last trade - 15.53pm 26/06/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |